Rapid network meta-analysis using data from Food and Drug Administration approval packages is feasible but with limitations.

ABSTRACT:

Objective

To test rapid approaches that use Drugs@FDA (a public database of approved drugs) and ClinicalTrials.gov to identify trials and to compare these two sources with bibliographic databases as an evidence base for a systematic review and network meta-analysis (NMA).

Study design and setting

We searched bibliographic databases, Drugs@FDA, and ClinicalTrials.gov for eligible trials on first-line glaucoma medications. We extracted data, assessed risk of bias, and examined the completeness and consistency of information provided by different sources. We fitted random-effects NMA models separately for trials identified from each source and for all unique trials from three sources.

Results

We identified 138 unique trials including 29,394 participants on 15 first-line

SUBMITTER: Wang L 

PROVIDER: S-EPMC6773505 | biostudies-literature | 2019 Oct

REPOSITORIES: biostudies-literature